CN102988403A - Injection medicine composition used for treating facial paralysis in acute stage - Google Patents

Injection medicine composition used for treating facial paralysis in acute stage Download PDF

Info

Publication number
CN102988403A
CN102988403A CN2012105490169A CN201210549016A CN102988403A CN 102988403 A CN102988403 A CN 102988403A CN 2012105490169 A CN2012105490169 A CN 2012105490169A CN 201210549016 A CN201210549016 A CN 201210549016A CN 102988403 A CN102988403 A CN 102988403A
Authority
CN
China
Prior art keywords
medicine composition
facial paralysis
acute stage
injection medicine
composition used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012105490169A
Other languages
Chinese (zh)
Inventor
祁建春
刘刚
祁智勤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2012105490169A priority Critical patent/CN102988403A/en
Publication of CN102988403A publication Critical patent/CN102988403A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses an injection medicine composition used for treating facial paralysis in acute stage, mainly comprising dexamethasone, anisodamine, cobamamide and lidocaine. The injection medicine composition disclosed by the invention has the effects of improving nutrition and metabolism of nervous tissues of the face, improving nutrition of local tissues, resisting inflammation and improving microcirculation. The therapeutic method has the advantages of high curative effect, available raw materials, low price and easy operation. The injection medicine composition disclosed by the invention is injected once every day, one treatment course comprises seven days (treating for 6 days and resting for 1 day), and generally a patient suffering from the facial paralysis in the acute stage can be healed for 2-3 treatment courses. Clinical verifications show that the effective rate reaches up to more than 98.4%.

Description

Be used for the treatment of the injectable drug combination of acute stage facial paralysis
Affiliated technical field
The technology of the present invention relates to the drug regimen for the treatment of the acute stage facial paralysis, specifically a kind of by 4 kinds of drug regimens formulated and to acute stage facial paralysis the drug regimen of obvious therapeutic action is arranged.
Background technology
Acute stage,, facial paralysis was the outpatient service commonly encountered diseases, and sickness rate is high and be difficult to cure.Because its pathogeny is complicated, the cause of disease is still not clear so far, and its treatment has become a clinical difficult problem, and many medical personnels and scientific research personnel try to explore.At present commonly used have a following Therapeutic Method: Chinese medicine, and acupuncture, etc., oral antiviral and vitamin, hormone medicine, but curative effect is all not bery definite.Often therapeutic process is complicated, and treatment cycle is long, causes very large misery to patient, and the expected value that patient's an urgent demand is cured is very high.Actively seeking a kind of true and reliable Therapeutic Method is the direction that we make great efforts.
Summary of the invention;
The object of the present invention is to provide a kind of injectable drug combination that can effectively treat the acute stage facial paralysis that has 4 kinds of drug regimens to form.
The object of the present invention is achieved like this, and drug regimen has following several; Anisodamine, dexamethasone, cobamamide, lignocaine, 5ml oral cavity special syringe form.Using method: with sucking behind the said medicine mix homogeneously in the special syringe of 5ml oral cavity, be expelled to Ipsilateral after the partly sterilised and lead nebula wind scoop place, positive cave, bring into play its therapeutical effect, generally weekly 6 times, 7 days is a course for the treatment of.
The present invention compared with prior art is the effective method for the treatment of at present the acute stage facial paralysis.Its ingredients namely can be removed its symptom again for the cause of disease.Because it is drawn materials conveniently, simple to operate, drug price is cheap, and determined curative effect is reliable.Through our treatment totally 2000 many cases clinical verifications, effective percentage reaches more than 98.4%, and basic the healing welcome by extensive patients deeply.
The specific embodiment
1 Anisodamine 10mg, dexamethasone 10mg, cobamamide 1.0mg, lignocaine 1ml, the special-purpose needle tubing in 5ml oral cavity are for subsequent use.
2 operational approach: with mix homogeneously in each a suction needle tubing of said medicine, the strong side of order head deflection is behind the iodophor disinfection with the 5ml syringe, be injected at respectively and lead positive cave and nebula wind scoop, the nebula wind scoop thrusts a little, keeps straight on to thrust 2.5 centimeters, nearly stylomastoid foramen place behind the resorption depletion of blood, is injected at Ipsilateral nebula wind scoop place.Inject every day 1 time, 7 days is a course for the treatment of, (treat and had a rest 1 day in 6 days) general 2-3 course for the treatment of, can cure.
3 therapeutic evaluatioies and effect: the facial expression myokinesis is symmetrical, and this therapy is treated 2000 many cases altogether in order to cure, the basic healing, and total effective rate reaches more than 98.4%.

Claims (2)

1. one kind has 4 kinds of ingredients, is used for the treatment of the method for the injectable drug combination of acute stage facial paralysis:
Figure FSA00000825218000011
2. said above drug regimen and implement to finish with following method according to claim 1:
The weighting profit requires all medicines of 1 to suck in the special syringes of 5ml oral cavity, is expelled to respectively that Ipsilateral leads positive cave and the nebula wind scoop gets final product.
CN2012105490169A 2012-12-06 2012-12-06 Injection medicine composition used for treating facial paralysis in acute stage Pending CN102988403A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012105490169A CN102988403A (en) 2012-12-06 2012-12-06 Injection medicine composition used for treating facial paralysis in acute stage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012105490169A CN102988403A (en) 2012-12-06 2012-12-06 Injection medicine composition used for treating facial paralysis in acute stage

Publications (1)

Publication Number Publication Date
CN102988403A true CN102988403A (en) 2013-03-27

Family

ID=47917831

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012105490169A Pending CN102988403A (en) 2012-12-06 2012-12-06 Injection medicine composition used for treating facial paralysis in acute stage

Country Status (1)

Country Link
CN (1) CN102988403A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024051845A1 (en) * 2022-09-09 2024-03-14 北京达尔文细胞生物科技有限公司 Pharmaceutical composition for preventing and treating sequelae stage facial nerve paralysis, and use thereof
WO2024153178A1 (en) * 2023-01-18 2024-07-25 北京达尔文细胞生物科技有限公司 Pharmaceutical composition having early-stage peripheral facial paralysis treatment effect, and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
冯立新: "穴位注射临床应用举隅", 《江西中医药》 *
张俊庭: "《中国中医特治新法大全》", 31 December 1996 *
褚韩生等: "中西医结合治疗周围性面神经麻痹24例", 《现代中西医结合杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024051845A1 (en) * 2022-09-09 2024-03-14 北京达尔文细胞生物科技有限公司 Pharmaceutical composition for preventing and treating sequelae stage facial nerve paralysis, and use thereof
WO2024051844A1 (en) * 2022-09-09 2024-03-14 北京达尔文细胞生物科技有限公司 Pharmaceutical composition for preventing and treating acute stage facial nerve paralysis and use thereof
WO2024051847A1 (en) * 2022-09-09 2024-03-14 北京达尔文细胞生物科技有限公司 Pharmaceutical composition for preventing and treating facial nerve micro-entrapment syndrome and use thereof
WO2024153178A1 (en) * 2023-01-18 2024-07-25 北京达尔文细胞生物科技有限公司 Pharmaceutical composition having early-stage peripheral facial paralysis treatment effect, and use thereof

Similar Documents

Publication Publication Date Title
CN101647917A (en) Traditional Chinese medicine externally-applied anaesthetic
CN102988403A (en) Injection medicine composition used for treating facial paralysis in acute stage
Tao et al. Case of professor Xu ZOU's acupuncture technique for “benefiting kidney and strengthening anti-pathogenic qi” in promoting the absorption of COVID-19
CN102198091B (en) Acupuncture point injection
CN103417622A (en) Stasis-reducing and venation-flowing medicated wine
CN101156942A (en) Medicine combination for treating relapse stomatocace and chronic pharyngitis
CN101607017A (en) A kind of oral Chinese medicine for the treatment of fracture
Data Acupuncture plus point-injection for 32 cases of obstinate urticaria
CN103263333A (en) Lung cancer metastasis therapy apparatus
CN103127473A (en) Pain-relieving paste
CN101336992B (en) Traditional Chinese medicine preparation for treating early burn or scald
CN102343038A (en) Medicament for treating cerebrosis such as hemiplegic cerebral palsy, falling sickness, Parkinson, headache, insomnia and the like
CN1660256A (en) Medication for treating cough caused by inflammation of upper respiratory tract
CN101904928A (en) Ointment for treating psoriasis
CN102935088A (en) Injection therapy and drug constitutes for curing recurrent aphthous ulcer
CN1214808C (en) Pills for promoting reunion of bone, muscle and ligament
CN204133965U (en) For the anti-air embolism syringe that cerebral angiography diagnosis or brain diseases are treated
CN101530448A (en) External Chinese medicinal plaster for treating traumatic injury
CN1935187B (en) Injectionagent for treating mammary gland proliferation
CN200960340Y (en) Injection needle for treating pharyngolaryngitis
CN1526430A (en) Fracture setting medicine powder and its prepn process
CN1679572A (en) Medicinal injection for treating primary mimic tic
CN1679588A (en) Medicinal composition for treating mimic tic
CN102764289A (en) Externally applied medicine for treating single poisonous wasp sting
CN101816730A (en) Chinese medicinal composition for treating fire tooth and decayed tooth

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130327